Literature DB >> 2429124

Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

B Asjö, L Morfeldt-Månson, J Albert, G Biberfeld, A Karlsson, K Lidman, E M Fenyö.   

Abstract

T-lymphotropic viruses were isolated from 31 patients with different clinical manifestations of human immunodeficiency virus (HIV) infection. Lymphocyte cultures from patients with the acquired immunodeficiency syndrome (AIDS) or pre-AIDS yielded virus rapidly, as indicated by high levels of reverse transcriptase (RT) activity in culture fluids. These viruses were able to establish a persistent infection in several T4-antigen-positive tumour cell-lines. In contrast, lymphocyte cultures from patients with mild or no symptoms yielded virus more slowly and the RT activity was low. Co-cultivation of slow/low-yielding lymphocytes with T4-positive tumour cell-lines showed no or only transient virus production. In 14 out of 23 cases virus could be detected by their fatal cytopathic effects on tumour cells. The relation between severity of illness and in-vitro replication potential of the viruses suggests that in the course of an infection selection may occur for HIV variants that replicate efficiently in T4 cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429124

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  181 in total

Review 1.  African enigma: key player in human immunodeficiency virus pathogenesis in developing countries?

Authors:  M Clerici; S Declich; G Rizzardini
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Evidence for a cytopathogenicity determinant in HIV-1 Vpr.

Authors:  Mohan Somasundaran; Mark Sharkey; Beda Brichacek; Katherine Luzuriaga; Michael Emerman; John L Sullivan; Mario Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

3.  Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants.

Authors:  P Westervelt; T Henkel; D B Trowbridge; J Orenstein; J Heuser; H E Gendelman; L Ratner
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 5.  HIV-1 tropism.

Authors:  Aikichi Iwamoto; Noriaki Hosoya; Ai Kawana-Tachikawa
Journal:  Protein Cell       Date:  2010-07-07       Impact factor: 14.870

6.  Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice.

Authors:  R M Scoggins; J R Taylor; J Patrie; A B van't Wout; H Schuitemaker; D Camerini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay.

Authors:  J A Nelson; S A Fiscus; R Swanstrom
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

8.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

Authors:  A B van't Wout; N A Kootstra; G A Mulder-Kampinga; N Albrecht-van Lent; H J Scherpbier; J Veenstra; K Boer; R A Coutinho; F Miedema; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Syncytium induction in primary CD4+ T-cell lines from normal donors by human immunodeficiency virus type 1 isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells.

Authors:  B J Todd; P Kedar; J H Pope
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.